INS and Obesity: Insulin resistance is an early feature of diabetes progression and our results call attention for further studies addressing the axis glucagon-cAMP-GSH as new therapeutic target for the treatment of insulin resistant states, a hallmark of type 2 diabetes and obesity (Fig 8).